8.360NOK-7.11%Mkt Cap: 1.99B NOKP/E: —Last update: 2026-06-01
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three cli…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.99B NOK
Enterprise Value1.94B NOK
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-45.91M NOK
Revenue/Share—
Last Price8.360 NOK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees8
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0013033795
Valuation
P/E (Trailing)—
P/E (Forward)Infinity
PEG—
EV/EBITDA-47.20
EV/Revenue—
P/S—
P/B-103.45
EPS (TTM)-0.43
EPS (Forward)0.00
52W Range
0.547056% of range14.46
52W High14.46 NOK
52W Low0.5470 NOK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE367.49%
ROA-426.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.82M NOK
CapEx (TTM)—
FCF Margin—
FCF Yield-1.39%
Net Debt2.25M NOK
Net Debt/EBITDA-0.05
Balance Sheet
Debt/Equity-0.67
Current Ratio0.46
Quick Ratio0.46
Book Value/Sh-0.0870 NOK
Cash/Share0.0280 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 NOK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateOct 4, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.237.99M
Float179.75M
Insiders37.39%
Institutions2.49%
Technical
SMA 509.039 (-7.5%)
SMA 2003.200 (+161.2%)
Beta-1.23
S&P 52W Chg27.70%
Avg Vol (30d)13.20M
Avg Vol (10d)8.55M
Technical Indicators
RSI (14)48.6
MACD0.1042
MACD Signal0.3351
MACD Hist.-0.2309
BB Upper11.31 NOK
BB Middle9.555 NOK
BB Lower7.799 NOK
BB Width36.76%
ATR (14)0.9951 NOK
Vol Ratio (20d)0.96x